美股新聞 標題聯播 · 近 24 小時 337 則 · 29 個來源 · 最新 9/20 04:53
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · SRRK近 30 天 19 則 · 第 1 / 1 頁
- This week in charts: GSK’s China deals, the $300M IPO club and selling the news
- Scholar Rock Holding (SRRK) Wins FDA Approval for ISEMBYLD. Can Add-On Use Scale?
- Scholar Rock (SRRK) Stock Fair Value Edges Higher After Isembyld Approval And Analyst Revisions
- Scholar Rock Faces Early Isembyld Launch Friction From FDA Safety Requirements, Truist Says
- Scholar Rock Marks 'Defining Moment' with First Muscle-Targeted Treatment for Spinal Muscular Atrophy
- SRRK Shares Pull Back After FDA Approval For Genetic Disease Drug — But Wall Street Hikes Price Targets
- Scholar Rock's Early FDA Approval on Spinal Muscular Atrophy Drug Seen as 'Positive Surprise,' UBS Says
- Scholar Rock Shares Rise 9.1% After FDA Approves ISEMBYLD for Spinal Muscular Atrophy
- Premarket movers: AI stocks slide on warnings, Rumble, Scholar Rock jump
- Scholar Rock SMA drug approved by FDA
- Second Time’s The Charm: FDA Clears Scholar Rock’s SMA Drug Ahead Of Deadline, SRRK Soars 15% After-Hours
- Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)
- Scholar Rock Receives FDA Fast Track Designation for Apitegromab Facioscapulohumeral Muscular Dystrophy (FSHD) Program as Participant Dosing Commences in Phase 2 FORGE Trial
- Scholar Rock to Present at Upcoming Investor Conferences
- Scholar Rock (SRRK) Stock Looks Stretched On Book Value But Strong On Returns
- Is Scholar Rock Holding (SRRK) Fairly Valued On Its Apitegromab Regulatory Progress?
- Scholar Rock (SRRK) Streamlines Apitegromab Filings After Catalent Shift Is Regulatory Strategy De-Risking The Story?
- SRRK Stock Gains After Company Drops Troubled Novo Nordisk-Owned Plant From FDA Filing
- Scholar Rock Removes Catalent Indiana From Apitegromab BLA as Fill-Finish Facility
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。